(EQQB) EQQQ NASDAQ-100 Acc - Overview
Etf: Technology, Consumer, Healthcare, Communication
| Risk 5d forecast | |
|---|---|
| Volatility | 21.3% |
| Relative Tail Risk | 0.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -5.87 |
| Character TTM | |
|---|---|
| Beta | 0.281 |
| Beta Downside | 0.476 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| CAGR/Max DD | 0.89 |
Description: EQQB EQQQ NASDAQ-100 Acc January 13, 2026
The Invesco EQQQ NASDAQ-100 UCITS ETF Acc (XETRA:EQQB) is a Germany-domiciled exchange-traded fund that aims to replicate the performance of the Morningstar US Large-Cap Growth NR USD index, effectively giving investors exposure to the 100 largest non-financial U.S. companies by market capitalisation, with a heavy tilt toward technology and consumer-discretionary firms.
Key metrics (as of the latest reporting period) include an expense ratio of 0.30 %, total assets under management of roughly €7 billion, and a dividend yield of about 0.5 % (accumulating). The fund’s top ten holdings-Apple, Microsoft, Amazon, Alphabet (Class C), Meta Platforms, Tesla, Nvidia, Costco, PepsiCo and Broadcom-account for roughly 45 % of the portfolio, meaning its performance is highly correlated with U.S. tech earnings and the broader macro-environment for growth stocks. Recent drivers have been the Fed’s stance on interest rates (higher rates tend to compress valuations for high-growth companies) and the ongoing semiconductor supply-chain recovery, which underpins earnings for many Nasdaq-100 constituents.
If you want a deeper, data-driven breakdown of how these factors translate into risk-adjusted returns, the ValueRay platform offers a transparent, model-agnostic view that can help you test the ETF’s sensitivity to different economic scenarios.
What is the price of EQQB shares?
Over the past week, the price has changed by -2.45%, over one month by -3.27%, over three months by -3.11% and over the past year by +1.29%.
Is EQQB a buy, sell or hold?
What are the forecasts/targets for the EQQB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 412.5 | 14.3% |
EQQB Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 3.85b EUR (3.85b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 3.85b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 3.85b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.95% (E(3.85b)/V(3.85b) * Re(6.95%) + (debt-free company))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)